Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
2040
Trial Sponsor
Clinical Trial Start Date
June 28, 2021
0Primary Completion Date
August 30, 2022
0Study Completion Date
2024
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
Placebo0
ARO-ANG30
Interventional Trial Phase
Phase 20
Participating Facility
Official Name
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia0
Last Updated
October 24, 2022
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Investigator0
Outcomes Assessor0
Participant0
Care Provider0
Study summary
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
